US · Healthcare · Biotechnology
EPS came in at -0.26 against a street estimate of -0.28 — a beat of 7.1%.
Analysts rate Sagimet Biosciences Inc. Series A Common Stock a strong buy (11 buy, 0 hold, 1 sell out of 12) with an average price target of $27.91.
| Fund | Stake |
|---|---|
| BlackRock Inc | 20.22% |
| Balyasny Asset Management LLC | 11.15% |
| Woodline Partners LP | 9.23% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 9.00% |
| Vanguard Capital Management, LLC | 7.89% |
| Bvf Inc | 7.69% |
| Caligan Partners LP | 7.69% |
| Affinity Asset Advisors, LLC | 7.68% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 HEADLINE NUMBERS • Sagimet Biosciences entered into an underwriting agreement on September 30, 2026, for a public offering expected to close on Octob | 2026-10-01 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • On September 30, 2026, Sagimet Biosciences announced positive 52-week results from the Phase 3 ASC40-304 open-label extension tria | 2026-09-30 |
| Company announcement · Q3 2026 SAGIMET BIOSCIENCES INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Sagimet Biosciences Inc. (Nasdaq: SGMT) • Headquarters: 950 Tower Lane, Suite 150 | 2026-08-13 |
| Quarterly report · Q2 2026 SAGIMET BIOSCIENCES INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash Position: $165.9 million in cash and cash equivalents as of June 30, | 2026-08-11 |
| Results announced · Q3 2026 SAGIMET BIOSCIENCES INC. – Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash, cash equivalents and marketable securities: $257.6 million as of June | 2026-08-11 |
| Reg FD disclosure · Q3 2026 SAGIMET BIOSCIENCES INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Sagimet Biosciences Inc. (Nasdaq: SGMT) • Report Date: July 20, 2026 • Company St | 2026-07-21 |
| Board / officer change · Q2 2026 SAGIMET BIOSCIENCES INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company held 2026 Annual Meeting of Stockholders on June 12, 2026 • 32,017,613 shares | 2026-06-12 |
| Quarterly report · Q1 2026 SAGIMET BIOSCIENCES INC. - Q1 2026 SUMMARY HEADLINE NUMBERS • Cash and Marketable Securities: $104.5 million as of March 31, 2026 (cash: $36.6 milli | 2026-05-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sagimet Biosciences Inc. Series A Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.